ArticleCureus2025
Occurrence of Slow Flow/No-Reflow in Primary Percutaneous Coronary Intervention: Predictors, Management, and Outcomes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of endothelial glycocalyx degradation with post-PCI slow flow phenomenon in STEMI patients: a prospective observational study.Cardiovascular diagnosis and therapy · 2026Article
- Risk factors for Post-PCI cardiovascular events in coronary artery disease patients treated with clopidogrel combined with aspirin.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Slow flow/no-reflow (SF/NR) can undermine effective reperfusion during primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Identifying patients at risk before device escalation may enable protocolized microvascular-protection strategies within STEMI systems of care. Objective This study aimed to determine the prevalence of SF/NR in STEMI treated with primary PCI, identify pre-PCI predictors, and assess short-term in-hospital outcomes associated with SF/NR. Methods In a prospective cohort at a high-volume tertiary center, we enrolled 226 consecutive STEMI patients treated between January 1, 2024, and December 31, 2024 (complete-case analysis). SF/NR was defined as final thrombolysis in myocardial infarction (TIMI) flow <3 in the absence of mechanical obstruction. Multivariable logistic regression estimated independent predictors (adjusted odds ratios (aORs) with 95% CIs). Discrimination was assessed using the area under the receiver operating characteristic curve (AUC) with bootstrap optimism correction. In-hospital outcomes included final TIMI 3 flow, ventricular arrhythmia, hemodynamic instability, heart failure, and death. Results SF/NR occurred in 65/226 patients (28.8%). Independent predictors were diabetes mellitus (aOR, 2.05; 95% CI, 1.07-3.91), TIMI thrombus grade 5 (aOR, 3.02; 95% CI, 1.55-5.87), and pre-PCI TIMI 0 flow (aOR, 3.85; 95% CI, 1.53-9.67); symptom-to-balloon time >6 h was not an independent predictor. Model discrimination was fair (AUC, 0.74; 95% CI, 0.67-0.81; optimism-corrected AUC, 0.73). Compared with patients without SF/NR, those with SF/NR had lower final TIMI 3 flow (43.1% vs 82.0%; difference, -38.9 percentage points; 95% CI, -51.0 to -26.8) and higher rates of ventricular arrhythmia (18.5% vs 5.6%; P = 0.004), hemodynamic instability (24.6% vs 8.6%; P = 0.002), heart failure (21.5% vs 9.3%; P = 0.01), and in-hospital mortality (7.7% vs 1.9%; P = 0.04). Conclusions In contemporary primary PCI for STEMI, SF/NR was common and associated more strongly with thrombus burden and absent antegrade flow, along with diabetes, than with delays >6 hours. A simple pre-PCI triad (diabetes, TIMI thrombus grade 5, and TIMI 0 flow) may help flag higher-risk cases and prompt early microvascular-protection measures; external validation is warranted prior to routine adoption.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.